Marimed Inc. (MRMD) — SEC Filings
Marimed Inc. (MRMD) — 21 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 11 8-K, 6 10-Q, 2 DEF 14A.
View Marimed Inc. on SEC EDGAR
Overview
Marimed Inc. (MRMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: MariMed Inc. reported a slight revenue increase for the three months ended September 30, 2025, reaching $40.764 million, up from $40.595 million in the prior year period. However, for the nine months ended September 30, 2025, revenue decreased marginally to $118.176 million from $118.760 million in
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 2 bearish, 19 neutral. The dominant filing sentiment for Marimed Inc. is neutral.
Filing Type Overview
Marimed Inc. (MRMD) has filed 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of MRMD's 20 recent filings, 2 were flagged as high-risk, 4 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $40.764M |
| Net Income | $(2.941)M |
| EPS | N/A |
| Debt-to-Equity | 2.51 |
| Cash Position | $6.596M |
| Operating Margin | N/A |
| Total Assets | $205.599M |
| Total Debt | $136.553M |
Key Executives
- Dr. Michael K. Weitz
- Ms. Jennifer L. Smith
- Edward Gildea
Industry Context
MariMed Inc. operates as a multi-state cannabis operator in the United States, developing, owning, and managing licensed facilities for cultivation, production, and dispensing of medical and adult-use cannabis. The industry is characterized by rapid growth, evolving state-level regulations, and increasing competition from both established players and new entrants. Companies like MariMed focus on developing proprietary brands and products to differentiate themselves in a crowded market.
Top Tags
financial-reporting (7) · operations (4) · 10-Q (4) · financials (4) · Cannabis Industry (3) · 8-k (3) · Quarterly Earnings (2) · Net Loss (2) · Financial Performance (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Revenue | $40.764M | Slight increase from $40.595M in Q3 2024 |
| YTD 2025 Revenue | $118.176M | Marginal decrease from $118.760M in YTD 2024 |
| Q3 2025 Net Loss | $(2.941)M | Widened from $(0.990)M in Q3 2024 |
| YTD 2025 Net Loss | $(9.815)M | Significantly widened from $(4.166)M in YTD 2024 |
| YTD 2025 Income Tax Provision | $6.281M | Increased from $3.211M in YTD 2024 |
| YTD 2025 Bad Debt Expense | $1.522M | Significant expense related to credit card service providers |
| Cash and Cash Equivalents | $6.596M | Decreased from $7.282M at Dec 31, 2024 |
| Total Liabilities | $136.553M | Increased from $129.442M at Dec 31, 2024 |
| Total Stockholders' Equity | $54.321M | Decreased from $58.547M at Dec 31, 2024 |
| Common Shares Outstanding | 394,452,517 | As of September 30, 2025, up from 381,476,581 at Dec 31, 2024 |
| Net Loss | $1.5M | Q2 2025, a swing from $1.2M net income in Q2 2024 |
| Year-to-Date Net Loss | $2.8M | Six months ended June 30, 2025, compared to $2.1M net income in prior year |
| SEC File Number | 000-54433 | Identifies MariMed Inc.'s filing with the SEC. |
| IRS Employer Identification No. | 27-4672745 | Tax identification number for MariMed Inc. |
| Revenue | 2.5 | This is a placeholder value as specific revenue figures are not detailed in the provided text. |
Frequently Asked Questions
What are the latest SEC filings for Marimed Inc. (MRMD)?
Marimed Inc. has 21 recent SEC filings from Mar 2024 to Nov 2025, including 11 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MRMD filings?
Across 21 filings, the sentiment breakdown is: 2 bearish, 19 neutral. The dominant sentiment is neutral.
Where can I find Marimed Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Marimed Inc. (MRMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Marimed Inc.?
Key financial highlights from Marimed Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MRMD?
The investment thesis for MRMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Marimed Inc.?
Key executives identified across Marimed Inc.'s filings include Dr. Michael K. Weitz, Ms. Jennifer L. Smith, Edward Gildea.
What are the main risk factors for Marimed Inc. stock?
Of MRMD's 20 assessed filings, 2 were flagged high-risk, 4 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Marimed Inc.?
Forward guidance and predictions for Marimed Inc. are extracted from SEC filings as they are enriched.